Humanigen, Inc. , (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company targeting the prevention and remediation of an immune hyper-response called cytokine typhoon with its flagship drug candidate, lenzilumab, today announced updates on its lenzilumab in the COVID -19 progression program, adding written title earned from the United States Food and Drug Administration (FDA) following a Type B meeting to download comments on Emergency Use Authorization plans ( USA). The FDA agreed that Companys’ planned submission would possibly be sufficient to assist a US application, topic for Phase 3 test data, and provided recommendations and assistance for the Companys Biologics license application and approval path. The company also announced several updates to its Phase 3 registration exam with lenzilumab, which continues to be registered in the United States and Brazil, and which has now been approved for expansion into Mexico. The randomized, double-blind, placebo-controlled phase 3 trial lately has a total of 29 approved sites with 24 hospitalized and hospitalized adult COVID-19 patients who are actively recruiting adult COVID-19 patients who are at high risk. of disease progression.
The FDA has been very helpful and has provided a transparent direction in our U. S. tender plan, said Cameron Durrant, MD, MBA, CEO of Humanigen. We are encouraged through our Type B assembly and remain confident in our program and preparation plans before a imaginable U. S.
Lenzilumab is one of the few Phase 3 remedy functions in progression for COVID-19 and has the prospect of being a first-line remedy to improve recovery time and avoid serious and life-threatening outcomes in patients hospitalized by COVID-19. of new check sites in Brazil and Mexico expands access to this study, which is critical for regions experiencing case accumulation, by adding centers that are already being registered in the United States in spaces called ‘hot spots’, Dale Chappell said. , MD, MBA, Chief Scientific Officer of Humanigen. The test record continues as we prepare to announce high-level knowledge in the fourth quarter. At the same time, we are proceeding with our large-scale commercial production efforts, having recently announced agreements with Thermo Fisher. and Lonza, in addition to Catalent, who deserve to guarantee access to lenzilumab if granted by the USA.
Key updates to the lenzilumab COVID-19 program include:
FDA Type B Updates:
Updates to the Phase 3 test program in the United States:
Update of the Phase 3 test program in Brazil:
Phase 3 test program updates in Mexico:
More main points on Humanigens systems can be found on COVID-19 on the Companys online page in www. humanigen. com under the COVID-19 tab, and the main points of the prospective Phase 3 registration exam in the United States can be discovered on Clinicaltrials . gov the CNT04351152 identifier.
About Humanigen, Inc.
Humanigen, Inc. is expanding its portfolio of preclinical and clinical remedies for the treatment of cancers and infectious diseases through its new gene neutralization and GM-CSF neutralization platforms. We believe that our GM-CSF gene editing and neutralization platform technologies have the potential to decrease the inflammatory cascade related to coronavirus infection. The company’s immediate goal is to save you or minimize the cytokine release syndrome that precedes severe lung disorder and ARDS in severe cases of SARS-CoV-2 infection. The company also aims to create next-generation gene-edited combinatorial CAR-T remedies that employ methods to improve efficacy while employing GM-CSF gene suppression technologies to control toxicity. Additionally, the company is developing its own portfolio of proprietary EphA3-CAR-T for various counterfeit cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the efficacy of its GM-CSF neutralization technologies (either by using lenzilumab as a neutralizing antibody or by deleting the GM-CSF gene) in admixture with other CAR-T T mobiles, bispecific killers or herbal (NK). initiate immunotherapy remedies to break the efficacy / toxicity link, adding to save it and / or treat graft-versus-host disease (GVHD) in patients undergoing mobile allogeneic hematopoietic stem transplantation (HSCT). Furthermore, Humanigen and Kite, a Gilead company, are comparing lenzilumab as a sequenced remedy with Yescarta (ciloleucel axicabtagene) in patients with relapsed or refractory giant mobile B lymphoma in a clinical collaboration. For more information, stop over at www. humanigen. com.
This press release includes forward-looking statements. Forward-looking statements reflect existing knowledge, assumptions, judgment and expectations of control regarding functionality or long-term occasions. While the control believes that the expectations reflected in those statements are reasonable, they cannot guarantee that such expectations will turn out to be adequate and you deserve to be aware that the actual occasions or effects may differ materially from those contained in the future. gaze statements. Words such as “will”, “expect”, “intention”, “plan”, “forward-looking”, “imaginable”, “objectives”, “accelerate”, “continue” and similar expressions identify forward-looking statements, including: without limitation , statements regarding our expectations for the Phase 3 review and long-term forward-looking progression of lenzilumab, our path to our planned submission and prospective receipt of an emergency use authorization and the next conceivable FDA BLA, and statements related to that of lenzilumab for use in the prevention or treatment of GvHD and, as a sequenced remedy with Kites Yescarta, in CAR-T therapies. Forward-looking statements are subject to a number of dangers and uncertainties, including but not limited to the dangers inherent in our lack of profitability; our reliance on partners to further expand our candidate products; prices related to CMC paints and the uncertainties inherent in the progression and launch of any new pharmaceutical product; the final results of an ongoing or long-term dispute; and the various dangers and uncertainties described in the “Risk Factors” sections and elsewhere in the Company’s periodic and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety through this warning. You deserve not to place undue reliance on forward-going statements, which relate only to the date of this release. We assume no legal responsibility to review or update any -Statements made in this press release to reflect occasions or cases after the date of this fact or to reflect new data or the occurrence of unforeseen occasions, as required by law.
1 Johns Hopkins University and Coronavirus Resource Center in Medicine. But it’s not the first time Across the county. Updated October 1, 2020. Retrieved October 1, 2020. https: //coronavirus. jhu. edu/us-map 2 The New York Times. Map of Brazil Covid and number of cases. Updated October 1, 2020. Retrieved October 1, 2020. https: //www. nytimes. com/interactive/2020/world/americas/brazil-coronavirus-cases. html 3 The New York Times. Covid World Map: Tracking the Global Epidemic. Updated October 1, 2020. Retrieved October 1, 2020. https: //www. nytimes. com/interactive/2020/world/americas/mexico-coronavirus-cases. html
Rockwell Automation acquires cybersecurity company
Bristol Myers Squibb will host a virtual opportunity for investors to discuss the effects of the Phase 3 True North trial comparing Zeposia® (ozanimod) on ulcerative colitis at UEG 2020 week
SHANGHI, October 2, 2020 / PRNewswire / – Ossen Innovation Co. , Ltd. (the “Company”) (Nasdaq: OSN), a China-based manufacturer of a variety of elegant surfaces, rare lands and metal materials of zinc precontrain, announced today that on September 22, 2020, the independent special committee (the “independent committee”) of the company’s board of directors (the “council”) was formed “to compare and revise the letter announced in the past of a pre-binding procurement proposal dated September 15, 2020 (the “privatization proposal”) , has hired Houlihan Lokey (China) Limited as an independent monetary adviser to lend a hand in this process.
The Board warns the company’s shareholders and others contemplating negotiating the company’s values that no resolution has been made related to the privatization proposal or any other strategic option that the company would possibly adopt. There is no guarantee that a final offer will be made, Any final agreement related to the proposed transaction will be executed, or that this transaction or any other transaction will be approved or completed. The Company assumes no legal responsibility to provide updates on this or any other transaction, as required by applicable law.
About Ossen Innovation Co. , Ltd.
Ossen Innovation Co. , Ltd. manufactures and sells a wide variety of smooth surface pre-stretched metal fabrics and pre-stretched metal fabrics coated with rare, zinc-coated earths. Corporate products are basically used in bridge construction, as well as on roads and other infrastructure projects. The company has two production plants located in Ma’anshan, Anhui Province, China and Jiujiang, Jiangxi Province, China.
Safe Harbor Statements
This press release would possibly involve forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and as explained in the Litigation. US Private Securities Reform Act. 1995. These forward-looking statements involve inherent threats and uncertainties that may also cause actual effects to differ materially from those projected or anticipated, adding, but not limited to, threats similar to the expected time and probability. the final touch on a prospective transaction with Pujiang International Group Limited or any other party, adding the threat that the prospective transaction will not occur and the threat that any announcements related to the prospective transaction may potentially harm the Company’s inventory market value , as well as the threats described in the public documents filed through the Company with the Securities and Exchange Commission, adding the Company’s Annual Report on Form 20-F, as amended. All information provided in this press release is as of the date of this press release. Except as required by law, the Company assumes no legal responsibility to publicly update or revise forward-looking statements, whether as a result of new data, long-term occasions or otherwise, after the date the statements were made. or to reflect the occurrence. of unforeseen occasions.
For more information, contact:
Wei Hua, CEO Email: [email protected] Phone: 86-21-6888-8886 Web: www. osseninnovation. com
Investor Relations IRTeléphone: 1-347-393-4230 Email: [email protected]
Landmark Recovery has announced the opening of a new drug and alcohol recovery center for hospitalized patients in Indianapolis. Its former site in Carmel, Indiana, will reopen on October 6 under the leadership of its sister company, Praxis through Landmark Recovery, to Drug and Alcohol Detox middle targeting Medicaid Due to coVID’s increased demand and negative effects on intellectual fitness and addiction services, Landmark Recovery is expanding bed availability and insurance offerings by opening up those new buildings.
Landmark Recovery of Indianapolis opened on September 30 and now offers residential treatment, detoxification, partial hospitalizations, intensive sessions, organization and individual outpatient treatment led through Master Point doctors, SMART recovery meetings, and 12-step recovery. 46278, the new location now houses 72 patients in a construction designed with non-unusual spaces, organizational treatment rooms, offices, a recreation area, a dining room and an education area.
While we are grateful to reach out to more people, we hope we don’t have to. The opioid crisis, pandemic and addiction in general have done so much damage to our society, Americans and families,” said Matt Boyle, CEO of Landmark Recovery. It’s devastating to see the effects of addiction and I can only hope that our other places in Indiana will start making a difference for our patients and their loved ones.
Praxis through Landmark Recovery will space 48 patients and provide residential remedies and life skills education to help patients repair hope, serve as a goal for their lives. The programs come with detoxification remedy for withdrawal symptoms, organization and individual healing sessions, family circle and counseling. Follow-up help for Praxis alum students through Landmark Recovery is located at 13590 North Meridian Street Carmel, IN 46032 and opens on Tuesday, October 6, 2020.
With the opening of Praxis, we plan to provide all patients with the quality care they deserve and the team they want to succeed over their addictions, said Rachel Washington, Executive Director of Praxis. Especially COVID, we are seeing more and more Americans affected by addictions. and we are here to satisfy this desire in the Indianapolis community.
About Landmark Recovery
Landmark Recovery, founded in 2016, provides individualized treatments, adding detoxification, detoxification for hospitalized patients and alcohol detoxification systems, extensive clinics and systems for older patients to combat addiction. Landmark has drug and alcohol rehabilitation centers in Indianapolis, Oklahoma City, Louisville and Lexington. you or someone you have enjoyed wants to recover, call 866-504-8545, or stop by www. landmarkrecovery. com.
About Praxis
Praxis through Landmark Recovery provides hospital treatment, adding detoxification, addiction and alcohol rehabilitation, life skills education, and extensive outpatients designed in particular for others with Medicaid to achieve their sobriety goals. If you or someone you enjoy wants to recover, call 866-504-8545 or stopover www. praxistreatment. com.
Perlu. com (Perlu), the professional netpaintings of brands and influencers, declared October 6 as the National Influencers Day to celebrate the global netpaintings of influencers and show the exclusive and attractive paintings that influencers make for brands and their committed followers.
According to Andres Echenique, CEO of Perlu, influencers have helped reshape the marketing of a top-down logo communication that serves as a service with consumers to a personalized equal-to-equal connection. . So we’re looking to create a day to recognize the contribution influencers have made and continue to make to marketing. The tenth anniversary of the launch of Instagram, a platform that has reshaped influence marketing, provides the best opportunity to do so.
In popularity of National Influencers Day, Perlu hosts the first Influencer Insight conference
i3CON will take position from 11:00 a. m. EDT to 3:00 p. m. EDT with what includes:
After the presentations and discussion panel, influencers will participate in a hackathon in which they will be divided into teams to collaborate and create the most productive influencer marketing crusade concept imaginable for i3CON sponsor UAE USA United. Once the fields have been tested by a jury, the winning team will get an economic prize of $5,000.
Influencers are no longer just a “channel” for transmitting messages. They are creators, innovators, visionaries and network leaders who represent the voice of the crowd. Finally, brands are beginning to perceive the true scope of their effect and value, and the time has come for influencers to be treated as true market partners, Echenique continued. This occasion is our way to keep influencers on top of market disruptions and advances and introduce them to new in-house customers to help them drive their careers.
For more information or to register for this informal event, please visit: www. nationalinfluencerday. com
About Perlu
Founded in 2017, Perlu. com is a professional network for brands and influencers, offering resilient teams that help members connect, collaborate and grow. Perlu is the only platform for influencers that serves as a professional home for influencers and their professional development. 30,000 influential people use Perlu to organize networks of influential people to marry in a wide variety of non-public content and brand opportunities.
As a result, Perlu’s network of influencers provides brands with the fastest and most effective tactics for locating and interacting with active and reliable influencers in each category. Over a hundred brands, adding Hulu, BMW, Baidu, Chobani and Mount Gay Rum. , lately they use Perlu to realize and maintain relationships with qualified influencers and their communities in influential research, strategy and marketing programs.
SHANGHAI, 2 October 2020 / PRNewswire / – Ossen Innovation Co. , Ltd. (the “Company”) (Nasdaq: OSN), a Chinese manufacturer of an ofArray.
Resort Hall of Fame
IVERIC Bio, Inc. (Nasdaq: ISEE) announced that on October 1, 2020, the corporation had awarded an aArray to a newly hired worker.
Humanigen, Inc. , (Nasdaq: HGEN) (Humanigen), a clinically staged biopharmaceutical company aimed at the prevention and remedy of an immune hyperresposed called ‘cytokine . . .
KB Home (NYSE: KBH) today announced the official opening of Flatiron Meadows Villas, a new townhouse enclave in Array.
Office Properties Income Trust (Nasdaq: OPI) announced the release of a press release containing its 3rd quarter 2020Array. .
Perlu. com (Perlu), the professional network of brands and influencers, declared October 6 as Influencers Day to celebrateArray. .
Landmark Recovery has announced the opening of a new drug and alcohol recovery center for hospitalized patients in Indianapolis. Its past locationArray. .
FANUC, a world leader in CNC, robotics and ROBOMACHINE, will launch its first virtual occasion called Take Control. . .
Dascena, Inc. , a corporate device learning diagnostic rule set that targets early disease intervention in patient care outcomes, todayArray . .
The mandatory cookies are surely for the proper functioning of the site. This category includes only cookies that provide the essential capabilities and security features of the website. These cookies do not buy any non-public information.